BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30117281)

  • 1. Long-term outcome of group D patients with negative serum anti-Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans.
    Han YM; Chung SJ; Choi JM; Lee C; Kim JS
    J Dig Dis; 2018 Sep; 19(9):529-539. PubMed ID: 30117281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
    Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
    Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
    Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
    Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.
    Cao Q; Ran ZH; Xiao SD
    J Dig Dis; 2007 Feb; 8(1):15-22. PubMed ID: 17261130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
    Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
    Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
    Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Barbosa J; Guilherme M; Moreira-Dias L; Lomba-Viana H; Silva R; Abreu N; Lomba-Viana R
    Neoplasia; 2004; 6(5):449-56. PubMed ID: 15548353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.
    Leja M; Cine E; Rudzite D; Vilkoite I; Huttunen T; Daugule I; Rumba-Rozenfelde I; Pimanov S; Liepniece-Karele I; Pahomova J; Purmalis K; Eglitis J; Pirags V; Dzerve V; Erglis A
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1410-7. PubMed ID: 23114744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.
    Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Long Q; Flanders WD; Bostick RM; Yuan Y
    Int J Cancer; 2015 Jan; 136(2):425-34. PubMed ID: 24895149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
    Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
    Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Negative Anti-
    Inoue M; Sawada N; Goto A; Shimazu T; Yamaji T; Iwasaki M; Tsugane S;
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):420-426. PubMed ID: 31826914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
    Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
    Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status.
    Yakut M; Örmeci N; Erdal H; Keskin O; Karayel Z; Tutkak H; Soykan I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):302-11. PubMed ID: 23137754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.
    Shafaghi A; Mansour-Ghanaei F; Joukar F; Sharafkhah M; Mesbah A; Askari K; Geranmayeh S; Mehrvarz A; Souti F; Sokhanvar H; Fakhrieh S; Aminian K; Yousefi-Mashhour M; Khosh-Sorur M; Rasoulian J
    Asian Pac J Cancer Prev; 2013; 14(6):3931-6. PubMed ID: 23886209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
    Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
    Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study.
    Sipponen P; Ranta P; Helske T; Kääriäinen I; Mäki T; Linnala A; Suovaniemi O; Alanko A; Härkönen M
    Scand J Gastroenterol; 2002 Jul; 37(7):785-91. PubMed ID: 12190091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study.
    Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Bostick RM; Wu X; Yuan Y
    Am J Gastroenterol; 2017 May; 112(5):704-715. PubMed ID: 28323271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti- CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran.
    Mansour-Ghanaei F; Joukar F; Rajpout Y; Hasandokht T
    Asian Pac J Cancer Prev; 2014; 15(18):7635-8. PubMed ID: 25292040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and
    Koivurova OP; Koskela R; Blomster T; Ala-Rämi A; Lumme H; Kettunen O; Hukkanen J; Karttunen TJ; Mäkinen M; Ronkainen J; Syrjänen K
    Anticancer Res; 2021 Nov; 41(11):5527-5537. PubMed ID: 34732423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
    Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
    Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.